The company said Wednesday that Soliqua 100/33 (insulin glargine 100 units/ml and lixisenatide 33 mcg/ml) comes in a single, prefilled SoloStar pen with a dosage range of 15 to 60 units and two starting doses to support patients’ insulin needs. Soliqua 100/33 was approved by the U.S. Food and Drug Administration (FDA) on November 21, 2016.
Approved in late November, Soliqua 100/33 is indicated to help improve blood sugar control in adults with type 2 diabetes, when used with diet and exercise in people who are not controlled with long-acting insulin (less than 60 units daily) or lixisenatide.
“We are encouraged by the potential of Soliqua 100/33, which has demonstrated superior HbA1c lowering versus Lantus,” stated Peter Guenter, executive vice president and head of the global diabetes and cardiovascular business unit at Sanofi. “By offering Soliqua 100/33 — a product containing both a basal insulin and a GLP-1 therapy — at a competitive price while facilitating patient access, we believe we are providing value to patients and the health care system.”
Sanofi said Soliqua 100/33 is priced at $127 for a 300-unit pen (daily wholesale acquisition cost), which translates into $19.90 per day at the average final dose of 47 units used in the labeled clinical trial. The company added that it’s offering Soliqua 100/33 at a $0 co-payment for eligible U.S. patients with commercial insurance and is working to secure coverage for the product on health plans nationwide.
In addition, Sanofi is providing a tailored support program, called Soliqua 100/33 Coach, at no cost to adults with type 2 diabetes who have been prescribed Soliqua 100/33 by their doctor.
“Health care professionals need a broad range of treatments to individualize a patient’s diabetes care, particularly for the many adults living with diabetes who continue to face challenges in controlling their blood sugar levels even after treatment with basal insulin,” commented George Grunberger, M.D., chairman of the Grunberger Diabetes Institute in Bloomfield Hills, Mich. “This combination product provides a new option for many patients uncontrolled on basal insulin therapy or lixisenatide.”